- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07641764
3D Printed vs Ready-to-Wear Insoles for Diabetic Neuropathy (3DP-DPN)
14 juin 2026 mis à jour par: Anbreena Rasool, University of Faisalabad
Comparative Effect of 3D Printed Customized Insoles and Ready to Wear Insoles on Plantar Pressure Changes in Patients With Diabetic Neuropathy
Diabetic neuropathy is a condition caused by chronic high blood glucose levels that damage nerves over time, frequently causing abnormal plantar pressure and increasing the risk of foot ulcers and impaired mobility.
Insoles are widely used to redistribute pressure and improve comfort.
This study compares the effect of 3D printed customized insoles versus ready-to-wear insoles on plantar pressure changes in patients with diabetic neuropathy.
The study is a randomized controlled trial with 22 participants randomly allocated to two groups: one receiving 3D printed customized insoles and the other receiving ready-to-wear insoles.
Plantar pressure is measured using piezoresistive sensors and an Arduino Nano Unit.
Secondary outcomes include foot health status (FSHQ questionnaire), satisfaction with assistive technology (QUEST 2.0), and neuropathy severity (NSS and NDS questionnaires).
Assessments occur at baseline, 4 weeks, and 8 weeks.
Aperçu de l'étude
Statut
Actif, ne recrute pas
Les conditions
Intervention / Traitement
Description détaillée
This is a single-blind, parallel-group randomized controlled trial conducted at DHQ-1 and DHQ-2 hospitals in Okara, Pakistan.
Participants are adults aged 35-65 years with diagnosed diabetic neuropathy who can walk independently without aids.
Exclusion criteria include foot ulcers, external wounds, recent surgery, major limb amputation, foot drop, peripheral vascular disease, neuromuscular diseases, and Charcot arthropathy.
A consecutive sampling technique is used to recruit 22 participants.
Randomization is performed using a computer-generated sequence.
Participants are blinded to their group allocation.
Group A receives 3D printed customized insoles tailored to individual foot morphology using 3D scanning and printing technology.
These insoles provide arch support and gait alignment.
Group B receives ready-to-wear insoles providing general cushioning and basic support.
Both groups follow an 8-week intervention protocol: participants wear insoles for a minimum of 6 hours per day, 5 days per week, and perform level walking on a 28-meter pathway at self-selected speed.
The protocol is divided into phases: weeks 1-2 for acclimatization and footwear assessment using Semmes-Weinstein 10g monofilament; weeks 3-4 for pressure adaptation and skin monitoring; weeks 5-6 for enhanced foot function and balance improvement; weeks 7-8 for final assessment.
Primary outcome: plantar pressure measured via piezoresistive sensors and Arduino Nano Unit.
Secondary outcomes: Foot Health Status Questionnaire (FSHQ), Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST 2.0), Neuropathy Symptom Score (NSS), and Neuropathy Deficit Score (NDS).
Data are collected at baseline, week 4, and week 8. Statistical analysis uses SPSS version 22.
Type d'étude
Interventionnel
Inscription (Estimé)
22
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Punjab Province
-
Faisalābad, Punjab Province, Pakistan, 3800
- The University of Faisalabad
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Age 35 to 65 years
- Diagnosed with diabetes mellitus
- Clinical diagnosis of diabetic peripheral neuropathy
- Ability to walk independently without walking aids
- Normal cognitive function
- Corrected or uncorrected vision sufficient for safe ambulation
- Willingness to provide written informed consent
Exclusion Criteria:
- Presence of active foot ulcer
- External wound on lower extremity
- History of lower limb surgery within past 6 months
- Major lower limb amputation
- Foot drop
- Peripheral vascular disease
- Neuromuscular diseases (e.g., stroke, Parkinson's disease, multiple sclerosis)
- Charcot arthropathy
- Inability to comply with study protocol
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Group A: 3D Printed Customized Insoles
Participants in this group receive 3D printed customized insoles tailored to individual foot morphology.
Insoles are designed to provide arch support and gait alignment.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following a phased protocol of acclimatization, pressure adaptation, and function improvement.
|
3D printed customized insoles are fabricated using 3D scanning of the participant's foot to capture individual morphology.
The insoles are printed using thermoplastic polyurethane (TPU) or similar 3D printing filament.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
|
Comparateur actif: Group B: Ready-to-Wear Insoles
Participants in this group receive prefabricated ready-to-wear insoles providing general cushioning and basic support.
Participants wear insoles for minimum 6 hours/day, 5 days/week for 8 weeks, following the same phased protocol as the experimental group.
|
Ready-to-wear insoles are prefabricated insoles providing general cushioning and shock absorption.
These insoles are not customized to individual foot morphology.
The intervention involves daily wear of insoles for minimum 6 hours per day, 5 days per week, for 8 weeks.
Participants perform level walking on a 28-meter pathway at self-selected speed.
Weekly assessments monitor adherence, skin condition, and comfort.
Patient education on foot care and insole use is provided.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Plantar Pressure Distribution
Délai: Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Plantar pressure is measured using piezoresistive sensors connected to an Arduino Nano Unit.
Participants walk barefoot across the sensor platform.
The sensor records pressure distribution across the plantar surface in kilopascals (kPa).
Higher pressure values indicate greater plantar load, which is associated with increased risk of foot ulceration.
Lower pressure values indicate better offloading.
|
Baseline (Week 0), Mid-intervention (Week 4), Post-intervention (Week 8)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Foot Health Status Questionnaire (FSHQ) Score
Délai: Baseline (Week 0), Week 4, Week 8
|
The Foot Health Status Questionnaire (FSHQ) is a validated instrument assessing foot-related quality of life.
It includes domains of foot pain, foot function, footwear, and general foot health.
Each item is scored on a Likert scale.
Minimum score is zero and maximum score is 100.
scores are generally classified into ranges such as Very Low: 0-24.9
Low:25-49.9
Medium: 50-74.9
High: 75-100 HIgher score indicates better foot health and lower score indicates worst foot health.
|
Baseline (Week 0), Week 4, Week 8
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Réel)
1 janvier 2026
Achèvement primaire (Estimé)
30 juin 2026
Achèvement de l'étude (Estimé)
15 juillet 2026
Dates d'inscription aux études
Première soumission
6 juin 2026
Première soumission répondant aux critères de contrôle qualité
6 juin 2026
Première publication (Réel)
11 juin 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
17 juin 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
14 juin 2026
Dernière vérification
1 juin 2026
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système endocrinien
- Maladies du système nerveux
- Maladies vasculaires
- Maladies cardiovasculaires
- Maladies neuromusculaires
- Maladies du système nerveux périphérique
- Diabète sucré
- Angiopathies diabétiques
- Complications du diabète
- Maladies de la peau
- Ulcère de la peau
- Ulcère de jambe
- Ulcère du pied
- Maladies de la peau et du tissu conjonctif
- Neuropathies diabétiques
- Pied diabétique
Autres numéros d'identification d'étude
- TUF/EIRB/ 195 /26
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .